Home » Enrollment Complete in Acorda's MS Trial
Enrollment Complete in Acorda's MS Trial
Acorda Therapeutics has completed enrollment for its Phase III trial of Fampridine-SR in multiple sclerosis (MS) patients.
The 240-patient trial is designed to evaluate Fampridine-SR in improving walking ability in people with MS.
Acorda said it expects data from the trial in the second quarter of 2008.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May